Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck & Co., Inc. : FDA Denies Merck Request to Block Generic Form of Nasonex

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2012 | 08:47pm CEST
   By Peter Loftus 
 

Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.

The U.S. Food and Drug Administration this month denied Merck's petition asking the agency not to approve applications by generic drug makers to sell certain proposed generic forms of Nasonex. Merck, of Whitehouse Station, N.J., had argued the FDA shouldn't approve any proposed generic copy that has a different formulation than Nasonex.

The FDA denial of Merck's petition follows a federal court ruling earlier this year finding that Apotex Corp.'s proposed generic version of Nasonex doesn't violate a Merck patent for the drug. Merck has appealed that patent ruling.

Both developments remove some obstacles to the market entry of competing generic versions of Nasonex before patent protection expires in 2018, which would hurt sales of the branded drug. The drug, which Merck obtained in its 2009 purchase of Schering-Plough, generated $960 million in sales for the first nine months of 2012.

Canada's Apotex wants to sell a generic version of Nasonex that is slightly different from the original. The proposed Apotex product would have the same active ingredient, mometasone furoate, but in a non-water formulation, whereas Merck's product has a water component.

In 2009, Merck filed a patent-infringement lawsuit against Apotex in response to Apotex's application to market the generic product. Apotex argued that its proposed product wouldn't infringe upon Merck's patent because it would be a non-water formulation of mometasone furoate.

Following an April trial in federal court in Trenton, N.J., U.S. District Judge Peter G. Sheridan in June ruled that Apotex's proposed product wouldn't infringe upon the Merck patent, though the judge upheld the patent's validity. Merck has appealed the ruling.

In July, Merck filed a so-called citizen petition asking the FDA to refrain from approving any application for a non-water version of Nasonex that relies upon clinical data for the original drug. Merck argued that the non-water version couldn't be considered as the pharmaceutical equivalent to Nasonex because there would likely be differences in how they are absorbed in the body.

Lawyers for Apotex objected to Merck's request in a November comment letter to FDA, saying there was established precedent for the agency to approve generic versions of branded drugs that contain slightly different forms of the same active ingredient.

In a Dec. 7 letter, the FDA denied Merck's petition, saying that a non-water form of mometasone could potentially be considered pharmaceutically and therapeutically equivalent to the water-based Nasonex, assuming other requirements are met.

"We were disappointed with the decision on the citizen petition," said Merck spokesman Ronald Rogers.

The FDA denial of Merck's petition doesn't amount to approval of Apotex's generic product; that review is pending.

Apotex spokesman Steve Giuli declined to comment.

Merck shares declined 38 cents to $43.85 Wednesday.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
03:11pCurrency and pricing squeeze GSK as new shingles vaccine shines
RE
11:46aShire bid marks Takeda's latest - and biggest - push for global status
RE
09:54aMERCK AND : adds affinity optimization to nanoscale synthesis system
AQ
04/24Women's Health Market Analysis on Segment, Trend, Growth, Volume, Size, Globa..
AQ
04/23MERCK AND : European Medicines Agency Validates Type II Variation for Merck&rsqu..
BU
04/23MERCK AND : Climbs on Goldman Upgrade
AQ
04/22MERCK AND : Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamas..
PU
04/20MERCK AND : Advances Clean Energy Goals with Invenergy
AQ
04/20MERCK AND : Announces First Phase Three Studies for PCV-15 its Investigational P..
AQ
04/19MERCK AND : P&G Boasts Better Bottom Line
AQ
More news
News from SeekingAlpha
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/24Early-stage study of Keytruda/radiotherapy combo in bladder cancer suspended 
04/23EMA accepts Merck's marketing application for Keytruda for first-line lung ca.. 
04/23CELGENE : Bold Pursuits In Science With 24.66% Discount 
04/23Premarket analyst action - healthcare 
Financials ($)
Sales 2018 41 913 M
EBIT 2018 13 848 M
Net income 2018 8 764 M
Debt 2018 13 776 M
Yield 2018 3,23%
P/E ratio 2018 18,96
P/E ratio 2019 15,71
EV / Sales 2018 4,20x
EV / Sales 2019 4,03x
Capitalization 162 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,4 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.79%162 398
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
AMGEN0.44%116 720